Trin AMD Gwlyb ar gyfer y llygad cyntaf a’r ail lygad gan ddefnyddio’r cyffur Aflibercept a Lucentis;Adolygiad o’r holl gyffuriau a ddefnyddir i drin AMD Gwlyb sy’n destun treialon clinigol ar hyn o bryd er mwyn iddynt gael eu darparu ar gyfer triniaeth cyn gynted â’u bod yn cael eu trwyddedu;Cyflwyno’r driniaeth yn raddol gan ddefnyddio’r cyffur Aflibercept, gan sicrhau bod cyfradd  o 20% o leiaf o gleifion sy’n cael triniaeth gwrth-VEGF am AMD Gwlyb yn cael Aflibercept o fewn 12 mis;Gwerthuso’r protocolau  triniaeth gan Grŵp Retinol Cymru a’u dilysu trwy’r Grŵp Cynghori Arbenigol Offthalmolegol (“OSAG”) ar ôl chwe mis a’u hailwerthuso ar ôl deuddeg mis i sicrhau bod y gwasanaeth yn cyflwyno’r canlyniadau gorau i gleifion; aAtgyfeirio materion gwasanaeth fel y bo’n briodol o OSAG i’r Prif Gynghorydd Optometrig, i sicrhau bod cleifion yn cael eu hasesu a’u trin er mwyn cael y budd mwyaf o safbwynt eu golwg. Yn ogystal byddwn yn gofyn i’r Byrddau Iechyd adolygu’r systemau cofnodion electronig presennol i sicrhau data cywir a rhagolygon ariannu.
Treatment of Wet AMD for both first and second eyes using the drug Aflibercept and Lucentis;Review of all drugs for the treatment of Wet AMD currently undergoing clinical trials so that they may be provided for treatment as soon as they are licensed;Gradual phasing in of treatment using the drug Aflibercept, achieving a rate of at least 20% of patients receiving anti-VEGF treatment for Wet AMD receiving Aflibercept within 12 months;Appraisal of the treatment protocols by the Welsh Retina Group and ratified via the Ophthalmologist Specialist Advisory Group (“OSAG”) after six months and reappraisal after twelve months to ensure the service delivers the best outcomes for patients; andAppropriate referral of service issues from OSAG to the Chief Optometric Advisor, to ensure that patients are assessed and treated to receive the maximum visual benefit. In addition we will ask Health Boards to review the current electronic record systems to ensure accurate data and funding forecasts.